Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Innate Pharma SA ( (FR:IPH) ).
On November 5, 2025, Innate Pharma announced a conference call and webcast scheduled for November 13, 2025, to discuss its third-quarter 2025 results and business updates. The event will feature key executives, including the CEO and CFO, and will provide insights into the company’s recent progress. The announcement reflects Innate Pharma’s ongoing commitment to transparency and communication with its stakeholders, potentially impacting its market perception and investor relations.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company specializing in the development of immunotherapies for cancer patients. The company leverages its expertise in antibody engineering to create innovative therapeutic approaches, including monoclonal antibodies, Antibody Drug Conjugates, and multi-specific NK Cell Engagers through its proprietary ANKET® platform. Innate Pharma collaborates with biopharmaceutical companies such as Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD. It is listed on Euronext Paris and Nasdaq in the US.
Average Trading Volume: 211,261
Technical Sentiment Signal: Strong Sell
Current Market Cap: €148M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.